Initiating DESCOVY FOR PrEP®
Initiating DESCOVY FOR PrEP®1
Implementation fits within the paradigm of preventive health in primary care
Here’s a brief overview of what you need to do prior to initiating DESCOVY FOR PrEP. Select each section to learn more about screening and monitoring individuals on PrEP medication:
- DESCOVY FOR PrEP must be prescribed only to individuals confirmed to be HIV negative
- Drug-resistant HIV-1 variants have been identified with use of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) for HIV-1 PrEP following undetected acute HIV-1
- Do not initiate DESCOVY® for HIV-1 PrEP if signs or symptoms of acute HIV-1 infection are present unless negative HIV status is confirmed by a test approved or cleared by the FDA as an aid in the diagnosis of acute or primary HIV-1 infection
- If screening or symptoms consistent with acute HIV-1 infection indicate an individual may have become HIV positive while taking DESCOVY FOR PrEP, convert the HIV-1 PrEP regimen to an HIV treatment regimen until HIV-negative status is confirmed
- Test and monitor for chronic HBV and, if negative, consider vaccination
- Individuals should strictly adhere to the recommended DESCOVY FOR PrEP dosing schedule
- The effectiveness of DESCOVY FOR PrEP in reducing the risk of acquiring HIV-1 is strongly correlated with adherence
- Some individuals, such as adolescents, may benefit from more frequent visits and counseling
- DESCOVY FOR PrEP is not recommended in individuals with CrCl <30 mL/min
- Assess serum creatinine, estimated CrCl, urine glucose, and urine protein prior to or when initiating
- In individuals with chronic kidney disease, assess serum phosphorus
- DESCOVY FOR PrEP must be prescribed only to individuals confirmed to be HIV negative
- Drug-resistant HIV-1 variants have been identified with use of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) for HIV-1 PrEP following undetected acute HIV-1
- Do not initiate DESCOVY® for HIV-1 PrEP if signs or symptoms of acute HIV-1 infection are present unless negative HIV status is confirmed by a test approved or cleared by the FDA as an aid in the diagnosis of acute or primary HIV-1 infection
- If screening or symptoms consistent with acute HIV-1 infection indicate an individual may have become HIV positive while taking DESCOVY FOR PrEP, convert the HIV-1 PrEP regimen to an HIV treatment regimen until HIV-negative status is confirmed
- Test and monitor for chronic HBV and, if negative, consider vaccination
- Individuals should strictly adhere to the recommended DESCOVY FOR PrEP dosing schedule
- The effectiveness of DESCOVY FOR PrEP in reducing the risk of acquiring HIV-1 is strongly correlated with adherence
- Some individuals, such as adolescents, may benefit from more frequent visits and counseling
- DESCOVY FOR PrEP is not recommended in individuals with CrCl <30 mL/min
- Assess serum creatinine, estimated CrCl, urine glucose, and urine protein prior to or when initiating
- In individuals with chronic kidney disease, assess serum phosphorus
Prescribe DESCOVY FOR PrEP to appropriate individuals at risk of HIV as part of a comprehensive strategy that includes adherence to daily dosing and safer sex practices, including condoms, to reduce the risk of sexually transmitted infections (STIs).
DESCOVY® CO-PAY SUPPORTFDA=U.S. Food and Drug Administration; HBV=hepatitis B virus.